肿瘤标志物CA125，CA199，HE4及血HCG在卵巢恶性肿瘤中的表达与临床进展研究
Expression and Clinical Progress of Tumor Markers CA125, CA199, HE4 and HCG in Ovarian Malignant Tumors
DOI: 10.12677/ACM.2024.142615, PDF,   
作者: 茹一鸣, 陈志芳*：新疆医科大学第一附属医院，新疆 乌鲁木齐
关键词: 卵巢恶性肿瘤；肿瘤标志物CA125/CA199/HE4；血HCG；Ovarian Malignant Tumor； Tumor Markers CA125/CA199/HE4； Blood HCG
摘要: 卵巢恶性肿瘤是威胁女性身心健康的常见多发病，在妇科肿瘤中死亡率最高，故探究卵巢恶性肿瘤诊断或判断预后的生物标志物或血清学标志物，成为临床工作的一项重要研究领域。已有较多有关研究及文献报道，讨论血清肿瘤标志物CA125，CA199，HE4在卵巢恶性肿瘤中的表达与研究进展。近年，血HCG对于卵巢恶性肿瘤的影响也受到了关注。实验发现，血HCG，血HCG的产物可作为诊断卵巢恶性肿瘤的依据。另有实验证明，血HCG可刺激离体的卵巢恶性肿瘤细胞生长。或者，血HCG与卵巢恶性肿瘤上的HCG受体结合，直接或间接调控其生长。
Abstract: Ovarian cancer is a common and frequent disease that threatens women’s physical and mental health, with the highest mortality rate among gynecological tumors. Therefore, exploring bi-omarkers or serological markers for the diagnosis or prognosis of ovarian cancer has become an important research field in clinical work. There are many related studies and literature reports to discuss the expression and research progress of serum tumor markers CA125, CA199, HE4 in ovar-ian malignant tumors. In recent years, the effect of serum HCG on ovarian malignant tumors has also received attention. Experimental findings show that serum HCG and the products of serum HCG can be used as the basis for the diagnosis of ovarian malignant tumors. Other experiments have shown that HCG can stimulate the growth of ovarian cancer cells in vitro. Alternatively, blood HCG binds to HCG receptors on ovarian malignancies, directly or indirectly regulating their growth.
文章引用：茹一鸣, 陈志芳. 肿瘤标志物CA125，CA199，HE4及血HCG在卵巢恶性肿瘤中的表达与临床进展研究[J]. 临床医学进展, 2024, 14(2): 4435-4439. https://doi.org/10.12677/ACM.2024.142615

参考文献

[1] 陈真云, 李晓红, 李虹, 等. O-RADS分类结合CA125、HE4及ROMA在附件肿块中的诊断效能及影响因素[J]. 现代妇产科进展, 2023, 32(4): 287-292. [Google Scholar] [CrossRef] 
[2] Dochez, V., Caillon, H., Vaucel, E., Dimet, J., Winer, N. and Ducarme, G. (2019) Biomarkers and Algorithms for Diagnosis of Ovarian Cancer: CA125, HE4, RMI and ROMA, a Review. Journal of Ovarian Research, 12, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
[3] Olsen, M., Lof, P., Stiekema, A., et al. (2021) The Diagnostic Accuracy of Human Epididymis Protein 4 (HE4) for Discriminating between Benign and Malignant Pelvic Masses: A Systematic Review and Meta-Analysis. Acta Obstetricia et Gynecologica Scandinavica, 100, 1788-1799. [Google Scholar] [CrossRef] [PubMed]
[4] RAdu, M.R., Pradatu, A., Duica, F., et al. (2021) Ovarian Cancer: Bio-Markers and Targeted Therapy. Biomedicines, 9, Article No. 693. [Google Scholar] [CrossRef] [PubMed]
[5] 胡毓婷, 黄晓民, 缪恺, 等. 超声造影联合血清学在卵巢癌早期筛查中的应用研究[J]. 中国超声医学杂志, 2022, 38(1): 95-98. [Google Scholar] [CrossRef] 
[6] 邹建文, 高华. CEA、CA199、CA724和CA125在卵巢肿瘤中的诊断价值[J]. 山东医药, 2010, 50(7): 92-93. [Google Scholar] [CrossRef] 
[7] Nakagawa, N., Koda, H., Nitta, N., et al. (2015) Re-activity of CA19-9 and CA125 in Histological Subtypes of Epithelial Ovarian Tumors and Ovarian Endometriosis. Acta Medica Okayama, 69, 227-235.
[8] Gadducci, A., Guerrieri, M. and Cosio, S. (2019) Squamous Cell Carcinoma Arising from Mature Cystic Teratoma of the Ovary: A Challenging Question for Gynecologic Oncologists. Critical Re-views in Oncology/Hematology, 133, 92-98. [Google Scholar] [CrossRef] [PubMed]
[9] 王萍, 洪波, 郭鹏. 血清多指标联合经阴道彩超对上皮性卵巢恶性肿瘤的研究[J]. 中国超声医学杂志, 2022, 38(5): 561-565. [Google Scholar] [CrossRef] 
[10] 杨勇, 王冰. 人绒毛膜促性腺激素、人附睾蛋白 4、糖类抗原199联合检测对卵巢肿瘤的诊断价值[J]. 陕西医学杂志, 2019, 48(8): 1091-1093, 1101.
[11] Zhang, R., Siu, M.K.Y., Ngan, H.Y.S. and Chan, K.K.L. (2022) Molecular Biomarkers for the Early Detection of Ovarian Cancer. International Journal of Molecular Sciences, 23, Article No. 12041. [Google Scholar] [CrossRef] [PubMed]
[12] Galgano, M.T., Hampton, G.M. and Frierson, H.F. (2006) Compre-hensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853. [Google Scholar] [CrossRef] [PubMed]
[13] 杨玲, 周建政. 人附睾蛋白4在上皮性卵巢癌中的应用价值[J]. 临床与病理杂志, 2021, 41(3): 683-688. [Google Scholar] [CrossRef] 
[14] Zhang, C., Hu, H., Wang, X., et al. (2021) WFDC Protein: A Promising Diagnosis Biomarker of Ovarian Cancer. Journal of Cancer, 12, 5404-5412. [Google Scholar] [CrossRef] [PubMed]
[15] Lycke, M., Ulfenborg, B., Malchau Lauesgaard, J., Kristjansdottir, B. and Sundfeldt, K. (2021) Consideration Should Be Given to Smoking, Endometriosis, Renal Function (EGFR) and Age When Interpreting CA125 and HE4 in Ovarian Tumor Diagnostics. Clinical Chemistry and Laboratory Medicine, 59, 1954-1962. [Google Scholar] [CrossRef] [PubMed]
[16] Drapkin, R., Von Horsten, H.H., Lin, Y., et al. (2005) Human Epi-didy-Mis Protein 4 (HE4) Is a Secreted Glycoprotein That Is Overexpressed by Serous and Endometrioid Ovarian Car-cinomas. Cancer Research, 65, 2162-2169. [Google Scholar] [CrossRef] 
[17] Behrouzi, R., Barr, C.E. and Crosbie, E.J. (2021) HE4 as a Biomarker for Endometrial Cancer. Cancers (Basel), 13, Article No. 4764. [Google Scholar] [CrossRef] [PubMed]
[18] 中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(2021年版) [J].中国癌症杂志, 2021, 31(6): 490-500.
[19] Zhang, L., Chen, Y. and Wang, K. (2019) Comparison of CA125, HE4, and ROMA Index for Ovarian Cancer Diagnosis. Current Problems in Cancer, 43, 135-144. [Google Scholar] [CrossRef] [PubMed]
[20] Hada, A., Han, L.P., Chen, Y., et al. (2020) Compari-son of the Predictive Performance of Risk of Malignancy Indexes 1-4, HE4 and Risk of Malignancy Algorithm in the Triage of Adnexal Masses. Journal of Ovarian Research, 13, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
[21] Kinugasa, M., Nishirnura, R., Koizumi, T., et al. (1995) Combi-nation Assay of Urinary Beta-Core Fragment of Human Chorionic Gonadotropin with Serum Tumor Markers in Gyne-cologic Cancers. Japanese Journal of Cancer Research, 86, 783-789. [Google Scholar] [CrossRef] [PubMed]
[22] Wimalasena, J., Meehan, D., Dostal, R., Foster, J.S., Cameron, M. and Smith, M. (1993) Growth Factors Interact with Estradiol and Gonadotropins in the Regulation of Ovarian Cancer Cell Growth and Growth Factor Receptors. Oncology Research, 5, 325-337.
[23] Kraemer, S., Jaeger, W.H. and Lang, N. (2001) Growth Regulation Effects of Gonadotropin Induced Steroidogenic Response in Human Ovarian Cancer. Anticancer Research, 21, 2005-2010.

为你推荐